Welcome to the age of Moneyball Medicine For several years,…
Harry Glorikian’s love letter to the technology industry It’s the…
Why do many IVD companies face an uphill battle with…
Intellectual property considerations for molecular diagnostic development with emphasis on…
MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market How…
The MoneyBall solution to the healthcare crisis Many recent articles…
What’s the key to efficient IVD development? In the quest…
Learning from failure: What Theranos, Interleukin Genetics, & Courtagen can…